Business Daily Media

The Times Real Estate

.

Koru Lifescience preparing to send drug compounds to preclinical and clinical trials based on their study for Covid-19-PR Newswire APAC

  • Written by PR Newswire
Koru Lifescience preparing to send drug compounds to preclinical and clinical trials based on their study for Covid-19-PR Newswire APAC

AUCKLAND, New Zealand, Nov. 24, 2020 /PRNewswire/ -- Koru Lifescience, drug discovery, and advanced formulation research laboratory in Auckland, New Zealand, has identified several known drug compounds of value in their study for a treatment of Covid-19. The study reports shall be published after a scientific peer review within the next few months.

The finding is currently processed by Koru IP team before entering clinical trials scheduled for Q1 2021.

Joti Jain, Chairman of Koru, explained, "SARS-CoV-2 is an enveloped positive-sense RNA coronavirus, and the mechanisms that this virus uses to gain control of an infected cell and to replicate are not clearly understood. However, it is evident from the studies that this SARS-Cov-2 entirely relies on the cell molecular machinery and cell metabolites to survive and to replicate." Joti explained the survival mechanism of Sars-Cov-2 is what makes it so dangerous.

Sars-Cov-2 constitutes a new threat for the global community and economic growth; considering the Sars-Cov-2 Landscape and the potential impact worldwide, it was a no brainer to engage the resources and expertise towards researching Covid-19 therapy while placing several other research programs on hold. Another critical factor that led to these efforts was a growing concern regarding the availability of treatment and/or a vaccine for New Zealand. If the Covid-19 therapy were successful in human trials, this therapy would be offered to New Zealand at cost and priority as New Zealand remains Koru's priority. A similar offer shall be extended to several other countries facing severe economic and health challenges and might not be in the frontline of getting any vaccine or therapy in the foreseeable future. Further studies are in progress to have more data on the efficacy, dose determinations, and clinical outcome.

"It has been less than four months since we have started our research, and our team feels excited about the progress. It is incredible to be at this stage of research, where we have up-and-coming drug candidates that may have the potential to be repurposed for SARS-CoV-2 entry inhibition," Joti said.

From the initial phase, Koru has maintained a two-pronged approach that focuses equally on the entry inhibition and intracellular replication of Sars-Cov-2. Inhibition of viral entry is critical as Sars-Cov-2 can enter host cells via both endosomal and non-endosomal pathways. With this approach, Koru aims at preventing any escalation or progression of infection and the possibility of a Cytokine storm that may result in inflammatory damage, which is commonly seen in severe cases, explained Akhil Jain, CEO of Koru Lifescience.

Koru's drug research program is about rational drug discovery, focusing on practical and less toxic therapeutics compounds using polypharmacology as an approach; Koru is actively working on several targets. This approach has a significant impact on saving the cost of development, offers therapy for unmet medical needs, and lowers overall healthcare costs.

Contacts:

akhil@korulifescience.com +64278825555www.korulifescience.com[1][2]

References

  1. ^ akhil@korulifescience.com (www.prnasia.com)
  2. ^ www.korulifescience.com (www.korulifescience.com)

Read more https://www.prnasia.com/story/archive/3200566_AE00566_0

Businesses losing an average of $493k from data integrity flaws

Managing data responsibly and effectively for the AI age can give organisations a strong competitive advantage, but many are failing to harness th...

AI shopping disruptor Zyft raises $7.5M to lead the next gen of retail tech

Zyft appoints new CEO, Richard Stevens, to lead the latest Waller Group success story, valued at $30 million SYDNEY, 28 April 2025: Zyft, the lea...

Little known law offers savvy Kiwis the opportunity to supercharge their retirement savings

A little-known legal amendment is being leveraged by savvy New Zealanders and expat Brits to supercharge their retirement savings. Not many peop...

Cutting edge AI technology designed for doctors to reduce patient wait times launched in NZ

New Zealand specialist doctors now have access to Artificial Intelligence technology to help reduce patient wait times and experts say it could be...

Launchd Takes Off: Former AFL Stars Lead Tech-Powered Platform Set to Disrupt Talent and Influencer Marketing

Backed by Institutional Capital, Launchd Combines Five Leading Agencies and Smart Technology to Deliver Measurable Results Influencer marketing i...

Meet the Australian fintech unlocking rewards for small businesses

Small businesses make up 98 per cent of all businesses in Australia, yet they continue to bear the brunt of economic uncertainty. According to Credi...

Sell by LayBy